The VITAL E-newsletter is designed exclusively for clinicians who are teaching patients how to use Vivaglobin® therapy. It's your source for what's happening in the world of Vivaglobin® and its impact on your patient training efforts. Be sure to look for bimonthly issues of the VITAL E-newsletter for updates and complete coverage of current and relevant topics.
Forward to a colleague Like what you’re reading? Share it with a fellow healthcare professional – especially someone who might not yet know about Vivaglobin® or the VITAL™ training program.
For more information about Vivaglobin®, please visit www.vivaglobin.com.
Please review our Privacy Policy and Terms of Use. To unsubscribe from this newsletter, please click here.
Important Safety Information:
Immune Globulin Subcutaneous (Human), Vivaglobin®, is indicated for the treatment of patients with primary immunodeficiency (PI).
As with all immune globulin products, Vivaglobin® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.
Vivaglobin® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.
As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.
Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. In clinical studies, administration of Vivaglobin® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.
Please see full prescribing information.
CSL Behring
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901
